ClinicalTrials.govpublic full text
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
prostate cancer, metastatic castration-resistant prostate cancer, enzalutamide, ly2157299, tgf-β receptor inhibitor, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 835992
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.